Eli Lilly stockpiles $1.5B weight-loss pill ahead of FDA decision

• Eli Lilly has amassed $1.5 billion worth of its experimental oral weight-loss drug, orforglipron, in pre-launch inventory.
• This significant stockpile comes ahead of an anticipated FDA decision in April regarding the drug's approval.
• Last year, the company reported $550 million in pre-launch inventory for the same pill, indicating a rapid increase.
• Lilly aims to launch the weight-loss pill in multiple countries almost simultaneously if it receives US approval.
• Orforglipron received a fast-track review voucher from the FDA, potentially shortening the review period to 1-2 months.